View in EDS

Coagulation factor concentrates: past, present, and future.

Saved in:
Bibliographic Details
Title: Coagulation factor concentrates: past, present, and future.
Authors: Key, Nigel S., Negrier, Claude
Source: Lancet. 8/4/2007, Vol. 370 Issue 9585, p439-448. 10p. 1 Diagram, 2 Charts.
Subjects: Blood coagulation factors, Blood coagulation disorders, Hemophilia treatment, Blood transfusion, Blood coagulation, Prions, HIV infection transmission, Hepatitis C transmission, Biotechnology, Bioengineering
Abstract: This article presents the third installment on transfusion medicine examining the use of coagulation factor concentrates. Clotting factor transfusions are vital for patients with diseases such as haemophilia. In response to the many people infected by HIV and hepatitis C, a virus-free factor concentrate was created through a combination of improved donor selection, effective virucidal technology and recombinant protein expression biotechnology. These cleaned up the supply of coagulation factor concentrates but there are still therapeutic challenges including the transmission of prions and other pathogens, the formation of inhibitory alloantibodies and high costs. It is expected that bioengineered recombinant proteins that have been modified will be used more often in clinical practice.
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 26111744
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Coagulation factor concentrates: past, present, and future.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Key%2C+Nigel+S%2E%22">Key, Nigel S.</searchLink><br /><searchLink fieldCode="AR" term="%22Negrier%2C+Claude%22">Negrier, Claude</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 8/4/2007, Vol. 370 Issue 9585, p439-448. 10p. 1 Diagram, 2 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Blood+coagulation+factors%22">Blood coagulation factors</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+coagulation+disorders%22">Blood coagulation disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Hemophilia+treatment%22">Hemophilia treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+transfusion%22">Blood transfusion</searchLink><br /><searchLink fieldCode="DE" term="%22Blood+coagulation%22">Blood coagulation</searchLink><br /><searchLink fieldCode="DE" term="%22Prions%22">Prions</searchLink><br /><searchLink fieldCode="DE" term="%22HIV+infection+transmission%22">HIV infection transmission</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatitis+C+transmission%22">Hepatitis C transmission</searchLink><br /><searchLink fieldCode="DE" term="%22Biotechnology%22">Biotechnology</searchLink><br /><searchLink fieldCode="DE" term="%22Bioengineering%22">Bioengineering</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: This article presents the third installment on transfusion medicine examining the use of coagulation factor concentrates. Clotting factor transfusions are vital for patients with diseases such as haemophilia. In response to the many people infected by HIV and hepatitis C, a virus-free factor concentrate was created through a combination of improved donor selection, effective virucidal technology and recombinant protein expression biotechnology. These cleaned up the supply of coagulation factor concentrates but there are still therapeutic challenges including the transmission of prions and other pathogens, the formation of inhibitory alloantibodies and high costs. It is expected that bioengineered recombinant proteins that have been modified will be used more often in clinical practice.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=26111744
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(07)61199-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 439
    Subjects:
      – SubjectFull: Blood coagulation factors
        Type: general
      – SubjectFull: Blood coagulation disorders
        Type: general
      – SubjectFull: Hemophilia treatment
        Type: general
      – SubjectFull: Blood transfusion
        Type: general
      – SubjectFull: Blood coagulation
        Type: general
      – SubjectFull: Prions
        Type: general
      – SubjectFull: HIV infection transmission
        Type: general
      – SubjectFull: Hepatitis C transmission
        Type: general
      – SubjectFull: Biotechnology
        Type: general
      – SubjectFull: Bioengineering
        Type: general
    Titles:
      – TitleFull: Coagulation factor concentrates: past, present, and future.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Key, Nigel S.
      – PersonEntity:
          Name:
            NameFull: Negrier, Claude
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 08
              Text: 8/4/2007
              Type: published
              Y: 2007
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 370
            – Type: issue
              Value: 9585
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1